Loading
Life sciences · Journal article
World Journal of Pharmaceutical Research · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Alzheimer's disease (AD) is a neurological illness that affects older individuals and manifests as memory loss, cognitive decline, and linguistic impairment. As per the cholinergic theory, AD is mostly associated with a drop in acetylcholine (AChE) levels in the brain due to damage to cholinergic neurons. Therefore, increasing AChE with acetylcholinesterase inhibition is one of the most effective ways to treat AD symptoms. Sonmez et al.[42] A class of physical and cognitive impairments known as neurodegenerative diseases are brought on by the death of brain neurons. The most prevalent ND, Alzheimer's disease has been diagnosed in over 30 million people worldwide. Its symptoms, which start with recurrent short-term memory loss and advance to the degradation of higher cognitive skills including language and decision-making, are progressive and permanent. The disease has a significant social and economic impact because of the nature of these symptoms. This neurodegeneration is the consequence of several interconnected pathways supported by genetic and environmental variables rather than a single cause or process. Treatment has become challenging because of this intricate pathophysiology, and the medications currently on the market mainly relieve symptoms. Mzezewa et al.[33] Alois Alzheimer, a German neuro scientist, told about the Alzheimer’s disease in 1907. One of his patients had cognitive impairment, behavioral issues, and memory loss. Deficiencies. A biopsy revealed significant brain damage, including ageing plaques, neuron muddle known as neurofibrillary Muddle and axis. lack of Nerve cell and synapses, primarily in the hippocampus and neocortex association regions. The Pathophysiology of Alzheimer's disease begins with hippocampal shrinkage About 80% of people 65 and older have Alzheimer's; dementia only affects a small percentage of people at this age, but the frequency of dementia in Alzheimer's rises to 25% in people 80 and older. In older adults, Alzheimer's disease (AD) is the most common cause of dementia., and it is typified by growing neurological changes. De et al.[12]